Efficacy, safety and tolerability of combination therapy with timolol and dorzolamide in glaucoma and ocular hypertension

References

• VijayaLGeorgeRPaulPGPrevalence of open-angle glaucoma in a rural South India populationInvest Ophthalmol Vis Sci2005464461446716303934
   PubMed Web of Science ®Google Scholar
• IwaseASuzukiYAraieMTajimi Study Group, Japan Glaucoma SocietyThe Prevalence of Primary Open-Angle Glaucoma in Japanese: The Tajimi StudyOphthalmology20041111641164815350316
   PubMed Web of Science ®Google Scholar
• LeskeCMOpen-angle glaucoma – an epidemiologic overviewOphthalmic Epidemiol20071416617217896292
   PubMed Web of Science ®Google Scholar
• SakataKSakataLMSakataVMPrevalence of glaucoma in a South Brazilian population: Projeto GlaucomaInvest Ophthalmol Vis Sci2007484974497917962447
   PubMed Web of Science ®Google Scholar
• The Eye Diseases Prevalence Research GroupCauses and prevalence of visual impairment among adults in the United StatesArch Ophthalmol200412247748515078664
   PubMed Web of Science ®Google Scholar
• AstromSStenlundHLindenCIncidence and prevalence of pseudoexfoliations and open-angle glaucoma in northern Sweden: Results after 21 years of follow-upActa Opthalmol Scand200785832837
   Google Scholar
• AntonAAndradaMTMujicaVCalleMAPortelaJMayoAPrevalence of primary open-angle glaucoma in a spanish population: The Segovia StudyJ Glaucoma20041337137615354074
   PubMed Web of Science ®Google Scholar
• QuigleyHBromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol20069026226716488940
   PubMed Web of Science ®Google Scholar
• SchwartzKBudenzDCurrent management of glaucomaCurr Opin Ophthalmol20041511912615021223
   PubMedGoogle Scholar
• The Royal College of OphthalmologistsGuidelines for the management of open angle glaucoma and ocular hypertension http://www.rcophth.ac.uk. Accessed Dec 10, 2009
   Google Scholar
• MarquisREWhitsonJTManagement of glaucoma: focus on pharmacological therapyDrugs Aging20052212115663346
   PubMed Web of Science ®Google Scholar
• HoyngPFJvan BeekLMPharmacological therapy for glaucoma: a reviewDrugs20005941143410776828
   PubMed Web of Science ®Google Scholar
• HigginbothamEJHansenJDavisEJWaltJGGuckianAGlaucoma medication persistence with a fixed combination versus multiple bottlesCurr Med Res Opin2009252543254719731993
   PubMed Web of Science ®Google Scholar
• YehJKravitzDFrancisBRational use of the fixed combination of dorzolamide – timolol in the management of raised intraocular pressure and glaucomaClin Ophthalmol2008238939919668730
   PubMedGoogle Scholar
• BalfourJAWildeMIDorzolamide: a review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertensionDrugs Aging1997103844039143858
   PubMed Web of Science ®Google Scholar
• HeelRCBrogdenRNSpeightTMTimolol: a review of its therapeutic efficacy in the topical treatment of glaucomaDrugs1979173855369807
   PubMed Web of Science ®Google Scholar
• SugrueMFPharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitorsProg Retinal Eye Res20001987112
   PubMed Web of Science ®Google Scholar
• CoakesRLBrubakerRFThe mechanism of timolol in lowering intraocular pressure in the normal eyeArch Ophthalmol19789620452048363105
   PubMed Web of Science ®Google Scholar
• SonntagJRBrindleyGOShieldsMBEffect of timolol therapy on outflow facilityInvest Ophthalmol Vis Sci197817293296627467
   PubMed Web of Science ®Google Scholar
• ZimmermanTJHarbinRPettMTimolol and facility of outflowInvest Ophthalmol Vis Sci197716623624873723
   PubMed Web of Science ®Google Scholar
• PhylactosACTimolol inhibits adenylate cyclase activity in the iris-ciliary body and trabecular meshwork of the eye and blocks activation of the enzyme by salbutamolActa Ophthalmol (Copenh)1986646136223028033
   PubMed Web of Science ®Google Scholar
• OrmrodDMcClellanKTopical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucomaDrugs Aging20001747749611200308
   PubMed Web of Science ®Google Scholar
• ShellJWPharmacokinetics of topically applied ophthalmic drugsSurv Ophthalmol1982262072187041308
   PubMed Web of Science ®Google Scholar
• HasegawaTHaraKHataSBinding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitroDrug Metab Dispos1994223773828070313
   PubMed Web of Science ®Google Scholar
• WongBKBruhinPJBarrishANonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interactionDrug Metab Dispos1996246596638781782
   PubMed Web of Science ®Google Scholar
• MarenTHConroyCWWynnsGCOcular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitorJ Ocul Pharmacol Ther19971323309029437
   PubMed Web of Science ®Google Scholar
• WilkersonMCyrlinMLippaEAFour-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitorArch Ophthalmol1993111134313508216014
   PubMed Web of Science ®Google Scholar
• StrahlmanETippingRVogelRA six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Dorzolamide Dose-Response Study GroupAm J Ophthalmol1996122183194 Erratum: Am J Ophthalmol. 1996; 122:928.8694086
   PubMed Web of Science ®Google Scholar
• BiollazJMunafoABuclinTWhole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamideEur J Clin Pharmacol199547453460
   Web of Science ®Google Scholar
• Martens-LobenhofferJBandittPClinical pharmacokinetics of dorzolamideClin Pharmacokinet20024119720511929320
   PubMed Web of Science ®Google Scholar
• SieskyBHarrisABrizendineELiterature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flowSurv Ophthalmol200954334619171209
   PubMed Web of Science ®Google Scholar
• JanulevicieneIHarrisAKagemannLA comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patientsActa Ophthalmol Scand20048273073715606472
   PubMedGoogle Scholar
• ManniGCentofantiMGregoriDThe pulsatile ocular blood flow behaviour in open angle glaucoma patients after replacing timolol therapy with timolol and dorzolamide fixed combination: preliminary studyActa Ophthalmol Scand20022365556
   Google Scholar
• MartinezASanchezMA comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/timolol on retrobulbar haemodynamics in previously untreated glaucoma patientsCurr Med Res Opin200622677316393432
   PubMed Web of Science ®Google Scholar
• HarrisAJonescu-CuypersCPKagemannLEffect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucomaAm J Ophthalmol200113249049511589868
   PubMed Web of Science ®Google Scholar
• RolleTTofaniFBrogliattiBGrignoloFMThe effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patientsEye (Lond)2008221172117918202708
   PubMed Web of Science ®Google Scholar
• Fuchsjager-MayrlGWallyBRainerGEffect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertensionBr J Ophthalmol2005891293129716170119
   PubMed Web of Science ®Google Scholar
• GalassiFSodiARenieriGEffects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucomaOphthalmologica200221612312811919438
   PubMed Web of Science ®Google Scholar
• ClineschmidtCMWilliamsRDSnyderEA randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study GroupOphthalmology199810519529599787369
   PubMed Web of Science ®Google Scholar
• BoyleJEGhoshKGieserDKA randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzo lamide-Timolol Study GroupOphthalmology1998105194519519787368
   PubMed Web of Science ®Google Scholar
• FechtnerRDAiraksinenPJGetsonAJEfficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trialsActa Ophthalmol Scand200482424814982045
   PubMedGoogle Scholar
• SusannaRJrSheuWPComparison of latanoprost with fixed combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin AmericaClin Ther20042675576815220019
   PubMed Web of Science ®Google Scholar
• HonrubiaFMLarssonLISpiegelDA comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucomaActa Ophthalmol Scand20028063564112485286
   PubMedGoogle Scholar
• KonstasAGPapapanosPTersisITwenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combinationOphthalmology20031101357136012867391
   PubMed Web of Science ®Google Scholar
• OrzalesiNRissettiLBottoliAThe effect of latanoprost, brimonidinee and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertensionArch Ophthalmol200312145345712695241
   PubMed Web of Science ®Google Scholar
• OzturkFErmisSInanUComparison of ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6 month studyActa Ophthalmol Scand200785808317244215
   PubMedGoogle Scholar
• ChiselitaDAntohiIMedvichiRComparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, ran-domized, masked, cross-over design studyOftalmologia200549394516408674
   PubMedGoogle Scholar
• ParmaksizSYukselNKarabasVLA comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucomaEur J Ophthalmol200616738016496249
   PubMed Web of Science ®Google Scholar
• ColemanALLernerFBernsteinPA 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertensionOphthalmology20031102362236814644719
   PubMed Web of Science ®Google Scholar
• DayDGSharpeEDBeischelCJSafety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combinationEur J Ophthalmol20051533634215945001
   PubMed Web of Science ®Google Scholar
• SuzukiERJFranklinLMda SilvaLJComparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertensionCurr Med Res Opin2006221799180516968583
   PubMed Web of Science ®Google Scholar
• DayDGSchacknowCJWandMTimolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open angle glaucoma or ocular hypertensionAm J Ophthalmol200313513814312566015
   PubMed Web of Science ®Google Scholar
• HutzelmannJOwensSSheddenAComparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study GroupBr J Ophthalmol199882124912539924327
   PubMed Web of Science ®Google Scholar
• StrohmaierKSnyderEDuBinerHThe efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study GroupOphthalmology1998105193619449787367
   PubMed Web of Science ®Google Scholar
• SallKNGreffLJJohnson-PrattLRDorzolamide/timolol combination versus concomitant administration of brimonidinee and timolol: six-month comparison of efficacy and tolerabilityOphthalmology200311061562412623832
   PubMed Web of Science ®Google Scholar
• SolishAMDeLuccaPTCasselDADorzolamide/timolol fixed combination versus concomitant administration of brimonidinee and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measuresJ Glaucoma20041314915715097262
   PubMed Web of Science ®Google Scholar
• NixonDRYanDBChartrandJPPiemontesiRLSimonyiSHollanderDAThree-month, randomized, parallel-group comparison of brimonidinee-timolol versus dorzolamide-timolol fixed-combination therapyCurr Med Res Opin20092516451653
   Web of Science ®Google Scholar
• ArcieriESPereiraACAAndreoEGVFixed combination brimonidinee-timolol (Combigan) versus fixed combination dorzolamide-timolol (Cosopt) each given twice daily to reduce intraocular pressure in subjects with glaucoma or ocular hypertension [abstract no. E434–169]Invest Ophthalmol Vis Sci200647
   Google Scholar
• ZabriskieNNetlandPAComparison of brimonidinee/latanoprost and timolol/dorzolamide: two randomized, double masked, parallel clinical trialsAdv Ther2003209210012836809
   PubMed Web of Science ®Google Scholar
• SverrissonTGrossRPearsonJThe dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study GroupJ Glaucoma1999831532410529932
   PubMed Web of Science ®Google Scholar
• KalzunyJSzaflikJCzechowicz-JanickaKTimolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open angle glaucoma or ocular hypertensive patientsActa Ophthalmol Scand20038134935412859261
   PubMedGoogle Scholar
• ShinDHFeldmanRMSheuWPEfficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressureOphthalmology200411127628215019375
   PubMed Web of Science ®Google Scholar
• KonstasAGKozobolisVPLallosNDaytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%Eye2004181264126915218522
   PubMed Web of Science ®Google Scholar
• CvenkelBStewartJANelsonLAStewartWCDorzolamide/timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertensionCurr Eye Res20083316316818293187
   PubMed Web of Science ®Google Scholar
• ManniGDenisPChewPThe safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertensionJ Glaucoma20091829330019365194
   PubMed Web of Science ®Google Scholar
• MundorfTKRauchmanSHWilliamsRDNotivolRBrinzolamide/Timolol Preference Study Group. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol2008262362819668763
   PubMedGoogle Scholar
• TeusMAMigliorSLaganovskaGEfficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol2009362963619997566
   PubMedGoogle Scholar
• HatanakaMReisASanoMESusannaRJrAdditive Intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trialJ Glaucoma200992 [Epub ahead of print]
   Web of Science ®Google Scholar
• FechtnerRDMcCarrollKALinesCREfficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studiesJ Ocul Pharmacol Ther20052124224915969642
   PubMed Web of Science ®Google Scholar
• TsaiJCMcClureCARamosSECompliance barriers in glaucoma: a systematic classificationJ Glaucoma20031239339814520147
   PubMed Web of Science ®Google Scholar